[Skip to Navigation]
Comment & Response
February 2018

New Criteria Needed for Antisynthetase Syndrome

Author Affiliations
  • 1Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Universidad Autónoma de Madrid, Madrid, Spain
  • 2Division of Rheumatology, University and IRCCS Policlinico S Matteo Foundation, Pavia, Italy
  • 3Rheumatology Division and Epidemiology, University of Cantabria, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
JAMA Neurol. 2018;75(2):258-259. doi:10.1001/jamaneurol.2017.3872

To the Editor We have read with interest the article by Noguchi et al.1 Interestingly, 51 (11.1%) of the 460 Japanese patients with idiopathic inflammatory myopathies had positive aminoacyl transfer RNA synthetase antibodies. Twenty-four (47%) had distinctive histopathological findings that were characterized by perifascicular necrosis. This feature may help to differentiate patients with antisynthetase syndrome (ASSD) from other clinical entities included within the idiopathic inflammatory myopathy spectrum.1

Add or change institution